A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA)
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Rituximab (Primary) ; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms R4-RA
- 07 Feb 2018 Planned End Date changed from 1 Dec 2017 to 31 May 2019.
- 07 Feb 2018 Status changed to recruiting.
- 27 Jan 2018 Planned number of patients changed from 180 to 160.